WYSS-CENTER
29.9.2021 11:02:05 CEST | Business Wire | Press release
The Wyss Center announced today the CE (Conformité Européenne) mark Class I medical device for its Epios Cloud software. Epios Cloud is a web-based application for the online storage, processing and review of neural signals, including the ultra-long-term data recorded by an emerging generation of devices for remote brain monitoring. Its novel features allow seamless navigation of datasets covering months and years while access through a web browser allows clinicians to access patient data anywhere and anytime.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210929005365/en/
With the flexibility to connect to brain - or other bio-signal - recording devices over the web, Epios Cloud provides insights on multiple long-term data sources enabling clinicians to develop bespoke analytics to support personalized clinical decision making.
Clinicians are increasingly seeking options for outpatient neural monitoring over weeks to months. In epilepsy, home-based monitoring of brain activity during everyday life will help characterize the type and number of seizures, improve diagnosis and pre-surgical planning, and help build personalized treatment plans.
“We developed Epios Cloud as we needed software that would track not only when seizures occur but also the biosignals linked to epilepsy events. Epios Cloud allows us to synchronize neural data with heart rate or movement information over months or years. It gives us a glimpse of what is really going on in the brain during every-day life. In the future, additional data streams could easily be integrated into the platform to support other clinical applications. Importantly, centralized data storage will allow a fundamental change in automated analysis of neural data, allowing artificial intelligence algorithms to learn on an ever-growing global data lake – the development of which is already underway.” said Aleksander Sobolewski , PhD, Wyss Center Neuroscientist.
While current electroencephalogram (EEG) software is primarily optimized for the review of neural recordings that last minutes to hours, Epios Cloud is poised for the transition to longer-term recordings of weeks to months. Clinicians can also annotate the data with real-life events and develop novel analytics to automatically present regions of interest to complement visual screening.
George Kouvas , MBA, Wyss Center’s Chief Technology Officer said: “Epios Cloud is set to reveal new insights about epilepsy in individual patients – paving the way for personalized therapies. Now that Epios Cloud is CE marked, we look forward to connecting it to more brain recording modalities and to bringing this innovative long-term brain monitoring platform to more clinical or outpatient settings across Europe and beyond. Epios Cloud also has potential for use in stroke rehabilitation as well as neuromodulation of brain circuits for mental health applications.”
Epios Cloud is medical device software of Safety Class A as per IEC 62304 and CE-marked as Class I as per the Medical Device Directive 93/42/EEC. Epios Cloud is intended for displaying and reviewing electroencephalogram (EEG) recordings made by EEG devices using scalp and sub-scalp electrodes, heart rate and accelerometer measurements. The device is intended to be used by qualified medical practitioners. CE marking indicates that a product has been assessed and deemed to meet European Union safety, health and environmental protection requirements.
ENDS
About the Wyss Center for Bio and Neuroengineering, Geneva, Switzerland
The Wyss Center is an independent, non-profit research and development organization that advances our understanding of the brain to realize therapies and improve lives.
The Wyss Center staff, together with the Center’s academic, clinical and industrial collaborators, pursue innovations and new approaches in neurobiology, neuroimaging and neurotechnology.
Wyss Center advances reveal unique insights into the mechanisms underlying the dynamics of the brain and the treatment of disease to accelerate the development of devices and therapies for unmet medical needs.
The Wyss Center was established by a generous donation from the Swiss entrepreneur and philanthropist Hansjörg Wyss in 2014. Additional resources from funding agencies and other sources help the Wyss Center accelerate its mission.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210929005365/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom